2332840-70-5
2332840-70-5
Chemical Structure
BKI 1708
- CAS No.: 2332840-70-5
- Formula:C22H26N4O3
- Molecular Weight:394.47
InChIKey: MMLFTESUTQGDRQ-UHFFFAOYSA-N
SMILES: O=C(C1=C(N)N(CC(C)(CO)C)N=C1C2=CC3=C(C=C(C=C3)OC4CC4)C=C2)N
Biological Activity: BKI 1708 is a potent and orally active calcium-dependent protein kinase 1 (CDPK1) inhibitor (IC50 = 0.7 nM). BKI 1708 exhibits potent activity against Neospora (IC50 = 481 nM) and Toxoplasma (IC50 = 122 nM). BKI-1708 induces the formation of multinucleated complexes. BKI-1708 efficiently inhibits vertical transmission of both parasites and increases pup survival in mice[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BKI 1708 | BKI 1708 is a potent and orally active calcium-dependent protein kinase 1 (CDPK1) inhibitor (IC50 = 0.7 nM). BKI 1708 exhibits potent activity against Neospora (IC50 = 481 nM) and Toxoplasma (IC50 = 122 nM). BKI-1708 induces the formation of multinucleated complexes. BKI-1708 efficiently inhibits vertical transmission of both parasites and increases pup survival in mice. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. de Sousa MCF, et al. Efficacy of the bumped kinase inhibitor BKI-1708 against the cyst-forming apicomplexan parasites Toxoplasma gondii and Neospora caninum in vitro and in experimentally infected mice. Int J Parasitol Drugs Drug Resist. 2024 Aug;25:100553. [Content Brief]
- [2]. Wenlin Huang, et al. Development of 5-Aminopyrazole-4-Carboxamide-Based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. Journal of Medicinal Chemistry 2019, 62 (6), 3135-3146.
